The effect of five different transferrin variants (TFv1, TFv2, TFv3, TFv4, and TFv5) on the hemoglobin level, mean corpuscular volume (MCV), ferritin level, percent transferrin saturation (%TS), and the unsaturated iron binding capacity (UIBC) was investigated in subjects with defined HFE haplotypes, 919 persons undergoing health screening and 113 patients with clinical hemochromatosis. The most common variant is TFv4; the population distribution of this variant was also studied. None of the variants were found to have an effect on any of the parameters of iron metabolism that were investigated. Moreover, the frequency of these variants in patients with clinically significant hemochromatosis was no different from that in the general population. We conclude that these polymorphisms in transferrin do not play a role in the expression of hemochromatosis, nor do they produce any other significant changes in iron metabolism.
INTRODUCTION
In 1935 Sheldon suggested that "idiopathic" hemochromatosis was a hereditary disease. A number of genes were considered as candidates for the causation of this disorder, and among these was transferrin. Many genetic variants of this iron transport protein were known and in 1961 Trumbull and Giblett (1) concluded that the electrophoretic variants of this protein were not functionally different from the wild-type transferrin and that abnormalities in transferrin were, therefore, not responsible for hemochromatosis. After it was shown in 1975 by Simon et al. (2) that the disease was linked to the HLA locus, interest in candidate genes that were not on chromosome 6 disappeared. Indeed, when the HLA-linked gene, now designated HFE, was cloned in 1996 (3) it became apparent that most European patients with hemochromatosis were homozygous for a common mutation in this gene. It was also apparent, however, that mutations of HFE are not the sole cause of hemochromatosis. First of all, even in northern European patients with hereditary hemochromatosis, among whom the prevalence of HFE mutations is the highest, some 15% have no HFE mutation, even when the complete coding sequence is examined. Moreover, the clinical expression of the homozygous state varies widely. Many patients who are homozygous for the HFE mutation shown no manifestations of hemochromatosis and, indeed, appear to have normal iron stores. On the other hand, some patients with the disease become massively iron loaded and show substantial degrees of tissue damage. Clearly there are other factors that influence iron absorption.
From this point of view it is useful to examine candidate genes and candidate mutations to determine whether they are associated with any aberrations of iron metabolism or of erythropoiesis. One excellent such candidate is the transferrin receptor, particularly since the HFE protein complexes with this receptor (4, 5) . A single mutation (424A→G) causing a serine 142 → glycine substitution is a known polymorphism of the transferrin receptor and Tsuchihashi et al. (6) failed to find any evidence that the frequency of this mutation was higher either in patients with hemochromatosis either with or without HFE mutations than in the general population. Transferrin itself is another attractive candidate.
Transferrin is a highly polymorphic gene in which over 30 different genetic variants are known to exist. In the past, the transferrin variants were identified by differences in electrophoretic mobility. Most transferrin variants appear to be functionally normal. Only one transferrin variant has been identified that exhibited abnormal iron binding examined five allelic variants of transferrin. These are summarized in Table 1 . We have now investigated the effect of these on the severity of hemochromatosis and on parameters of iron metabolism in a large group of subjects.
MATERIALS AND METHODS
Two groups of subjects were studied. The first consisted of patients with clinical hemochromatosis with known HFE genotypes. These patients were subjects of a previous study (10) . The second group of patients comprised predominantly healthy individuals undergoing voluntary health screening in a health appraisal clinic who had volunteered to participate in a study of hemochromatosis. Not all parameters were available for every individual.
HFE genotypes were determined by allelespecific oligonucleotide hybridization, as described previously (10) . Transferrin genotypes were determined by polymerase chain reaction using the primer sets described in Table 2 to amplify regions of the transferrin gene containing the five known genetic variants. TFv1  TF917A  TF917G   TGGCAAAGACAAATCAA  TGGCAAAGGCAAATCAA  TFv2  TF986A  TF986G   CTCTGCCCACGGGTTTT  CTCTGCCCGCGGGTTTT  TFv3  TF2042A  TF2042G   ATACTTAGAAGAAGAATA  ATACTTAGGAGAAGAATA  TFv4  TF1795C  TF1795T   CCAGGAAACCTGTGGAG  CCAGGAAATCTGTGGAG  TFv5  TF1966A  TF1966G CGGAAACCAAGGACCTT CGGAAACCGAGGACCTT
The polymerase chain reaction was performed multiplexing the three primer sets in a single reaction. Essentially, the 50 µl reaction mix contained 50 ng of each primer, 250 ng of DNA, 0.1 M Tris HCl pH 8.8, 0.1 M (NH 2 ) 2 SO 4 , 50 mM MgCl 2 , 4 mg/ml BSA, and 1 U Taq polymerase. After an initial denaturation at 95 C for 2 min, the polymerase chain reaction was performed for 30 cycles at 95 C for 1 min, 61 C for 30 s and 72 C for 45 s. An aliquot of the amplified DNA fragments (5 µl) were spotted on 0.45 µM nylon membranes (Nytran supercharge 96 well plate) and allele specific oligonucleotide hybridization (ASOH) performed.
ASOH was performed for each transferrin variant. The primers used for ASOH are described in Table 3 .
Each oligomer was labeled by polynucleotide kinase using γ-ATP and the membranes hybridized with each oligomer separately. After hybridizing for 16-24 hr, the membranes were washed for 20-25 min at 48 C for TFv1, TFv4 and TFv5, and at 47 C for TFv2 and TFv3. The filters were exposed to xray film and autoradiography performed.
RESULTS AND DISCUSSION
We have genotyped 919 subjects undergoing health screening and 113 patients with documented hemochromatosis for five transferrin variants and for HFE mutations. The frequency of theTFv4 genotypes in 915 subjects of various ethnic backgrounds is presented in Table 4 . The prevalence of TFv4 as identified by DNA analysis is consistent with population studies that were performed using electrophoretic methods (8, 11) .
We examined the effect of the TFv4 polymorphism on the hemoglobin level, mean corpuscular volume (MCV), transferrin saturation (%TS) and unsaturated iron binding capacity (UIBC) in these 576 samples with the wild type HFE genotype (Table 5 , Figures 1-3) . We found that subjects who were heterozygous (C/T) or homozygous (T/T) for TFv4 exhibited normal levels of ferritin, transferrin saturation, unbound iron binding capacity, hemoglobin levels and MCV values when compared to samples with a normal with known HFE mutations at nt 187 or nt 845 also transferrin genotype (C/C). Analysis of 343 subjects failed to show any effect of the TFv4 polymorphism on these parameters (Table 6 ).
The other transferrin variants are much less prevalent in the population and only a relatively few individuals were detected who were heterozygous for these mutations. Out of 919 samples examined, These results are shown in Table 7 .
The penetrance of the homozygous HFE genotype seems to be relatively low with respect to clinical disease. Therefore, one would anticipate that if a mutation increased the severity of iron loading in patients who inherit this genotype it would be over-represented in the patient population when compared with the general population. This did not appear to be the case. As shown in Table 8 , the gene frequency of the TFv4 T haplotype was 0.1392, a value very similar to the 0.1501 that we found in the general population (Table 4) . Similarly, the frequency of this haplotype was not significantly altered in patients with hemochromatosis who did not have the homozygous 845A genotype. Similarly, the frequency of the less common TFv1, TFv2, TFv3, and TFv5 polymorphisms did not vary from that found in the general population.
Our studies indicate that the polymorphic transferrin variants investigated do not have a significant effect on iron metabolism and cannot explain the remarkable phenotypic variability that exists in hereditary hemochromatosis. It is possible that other mutations in transferrin might be responsible for some of the variability; indeed, patients with atransferrinemia are iron-loaded. However, it is likely that there are other gene(s) that play a more important role in modulating the effect of HFE mutations and in causing non-HFE-linked hemochromatosis.
